nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—TOP2A—Epirubicin—uterine cancer	0.115	0.15	CbGbCtD
Norfloxacin—TOP2A—Etoposide—uterine cancer	0.0893	0.117	CbGbCtD
Norfloxacin—SLC22A5—Dactinomycin—uterine cancer	0.0833	0.109	CbGbCtD
Norfloxacin—CYP2A6—Progesterone—uterine cancer	0.0799	0.105	CbGbCtD
Norfloxacin—CYP1A1—Progesterone—uterine cancer	0.0683	0.0897	CbGbCtD
Norfloxacin—TOP2A—Doxorubicin—uterine cancer	0.0609	0.08	CbGbCtD
Norfloxacin—CYP3A7—Progesterone—uterine cancer	0.0546	0.0718	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0546	0.0718	CbGbCtD
Norfloxacin—CYP3A5—Progesterone—uterine cancer	0.041	0.0538	CbGbCtD
Norfloxacin—CYP1A2—Progesterone—uterine cancer	0.0305	0.0401	CbGbCtD
Norfloxacin—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0241	0.0317	CbGbCtD
Norfloxacin—CYP3A5—Etoposide—uterine cancer	0.0183	0.0241	CbGbCtD
Norfloxacin—CYP3A4—Progesterone—uterine cancer	0.016	0.021	CbGbCtD
Norfloxacin—CYP1A2—Etoposide—uterine cancer	0.0137	0.0179	CbGbCtD
Norfloxacin—CYP3A4—Etoposide—uterine cancer	0.00715	0.00939	CbGbCtD
Norfloxacin—CYP3A4—Doxorubicin—uterine cancer	0.00488	0.00641	CbGbCtD
Norfloxacin—TOP2A—myometrium—uterine cancer	0.00114	0.0723	CbGeAlD
Norfloxacin—TOP2A—uterine cervix—uterine cancer	0.000891	0.0563	CbGeAlD
Norfloxacin—TOP2A—decidua—uterine cancer	0.000849	0.0536	CbGeAlD
Norfloxacin—TOP2A—endometrium—uterine cancer	0.000806	0.0509	CbGeAlD
Norfloxacin—TOP2A—mammalian vulva—uterine cancer	0.000779	0.0492	CbGeAlD
Norfloxacin—TOP2A—uterus—uterine cancer	0.000742	0.0469	CbGeAlD
Norfloxacin—TOP2A—female gonad—uterine cancer	0.000607	0.0384	CbGeAlD
Norfloxacin—SLC22A5—myometrium—uterine cancer	0.000606	0.0383	CbGeAlD
Norfloxacin—TOP2A—vagina—uterine cancer	0.000604	0.0381	CbGeAlD
Norfloxacin—TOP2A—Teniposide—Etoposide—uterine cancer	0.000599	0.136	CbGdCrCtD
Norfloxacin—TOP2A—Podofilox—Etoposide—uterine cancer	0.000599	0.136	CbGdCrCtD
Norfloxacin—CYP2A6—vagina—uterine cancer	0.000551	0.0348	CbGeAlD
Norfloxacin—TOP2A—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.111	CbGdCrCtD
Norfloxacin—SLC22A5—uterine cervix—uterine cancer	0.000472	0.0298	CbGeAlD
Norfloxacin—SLC22A5—renal system—uterine cancer	0.000441	0.0279	CbGeAlD
Norfloxacin—SLC22A5—endometrium—uterine cancer	0.000427	0.027	CbGeAlD
Norfloxacin—TOP2A—Methyltestosterone—Progesterone—uterine cancer	0.000426	0.0965	CbGdCrCtD
Norfloxacin—CYP1A1—epithelium—uterine cancer	0.000425	0.0269	CbGeAlD
Norfloxacin—CYP1A1—uterine cervix—uterine cancer	0.000422	0.0266	CbGeAlD
Norfloxacin—CYP3A5—uterine cervix—uterine cancer	0.000412	0.026	CbGeAlD
Norfloxacin—CYP1A2—renal system—uterine cancer	0.0004	0.0253	CbGeAlD
Norfloxacin—CYP1A1—renal system—uterine cancer	0.000394	0.0249	CbGeAlD
Norfloxacin—TOP2A—lymph node—uterine cancer	0.00039	0.0247	CbGeAlD
Norfloxacin—CYP3A5—renal system—uterine cancer	0.000386	0.0244	CbGeAlD
Norfloxacin—CYP1A1—mammalian vulva—uterine cancer	0.000369	0.0233	CbGeAlD
Norfloxacin—SLC22A5—female reproductive system—uterine cancer	0.000353	0.0223	CbGeAlD
Norfloxacin—CYP1A1—uterus—uterine cancer	0.000351	0.0222	CbGeAlD
Norfloxacin—SLC22A5—female gonad—uterine cancer	0.000322	0.0203	CbGeAlD
Norfloxacin—SLC22A5—vagina—uterine cancer	0.00032	0.0202	CbGeAlD
Norfloxacin—CYP1A1—female reproductive system—uterine cancer	0.000316	0.02	CbGeAlD
Norfloxacin—TOP2A—Daunorubicin—Epirubicin—uterine cancer	0.000312	0.0707	CbGdCrCtD
Norfloxacin—TOP2A—Idarubicin—Epirubicin—uterine cancer	0.000312	0.0707	CbGdCrCtD
Norfloxacin—TOP2A—Doxorubicin—Epirubicin—uterine cancer	0.000312	0.0707	CbGdCrCtD
Norfloxacin—CYP3A4—renal system—uterine cancer	0.000289	0.0183	CbGeAlD
Norfloxacin—TOP2A—Daunorubicin—Doxorubicin—uterine cancer	0.000289	0.0655	CbGdCrCtD
Norfloxacin—TOP2A—Idarubicin—Doxorubicin—uterine cancer	0.000289	0.0655	CbGdCrCtD
Norfloxacin—TOP2A—Epirubicin—Doxorubicin—uterine cancer	0.000289	0.0655	CbGdCrCtD
Norfloxacin—CYP1A1—female gonad—uterine cancer	0.000287	0.0182	CbGeAlD
Norfloxacin—CYP1A1—vagina—uterine cancer	0.000286	0.018	CbGeAlD
Norfloxacin—CYP3A5—female gonad—uterine cancer	0.000281	0.0178	CbGeAlD
Norfloxacin—CYP3A5—vagina—uterine cancer	0.000279	0.0176	CbGeAlD
Norfloxacin—TOP2A—Norethindrone—Progesterone—uterine cancer	0.000278	0.0629	CbGdCrCtD
Norfloxacin—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00027	0.00137	CcSEcCtD
Norfloxacin—Myalgia—Dactinomycin—uterine cancer	0.000268	0.00137	CcSEcCtD
Norfloxacin—Hypersensitivity—Progesterone—uterine cancer	0.000268	0.00137	CcSEcCtD
Norfloxacin—Mouth ulceration—Epirubicin—uterine cancer	0.000265	0.00135	CcSEcCtD
Norfloxacin—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000262	0.00133	CcSEcCtD
Norfloxacin—Asthenia—Progesterone—uterine cancer	0.000261	0.00133	CcSEcCtD
Norfloxacin—Hypoaesthesia—Etoposide—uterine cancer	0.000261	0.00133	CcSEcCtD
Norfloxacin—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00133	CcSEcCtD
Norfloxacin—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00133	CcSEcCtD
Norfloxacin—Pruritus—Progesterone—uterine cancer	0.000258	0.00131	CcSEcCtD
Norfloxacin—Oedema—Dactinomycin—uterine cancer	0.000257	0.00131	CcSEcCtD
Norfloxacin—Hypertonia—Epirubicin—uterine cancer	0.000257	0.00131	CcSEcCtD
Norfloxacin—Blood urea increased—Doxorubicin—uterine cancer	0.000256	0.0013	CcSEcCtD
Norfloxacin—Thrombocytopenia—Dactinomycin—uterine cancer	0.000252	0.00128	CcSEcCtD
Norfloxacin—Diarrhoea—Progesterone—uterine cancer	0.000249	0.00127	CcSEcCtD
Norfloxacin—Erythema multiforme—Etoposide—uterine cancer	0.000248	0.00126	CcSEcCtD
Norfloxacin—Anorexia—Dactinomycin—uterine cancer	0.000245	0.00125	CcSEcCtD
Norfloxacin—Mouth ulceration—Doxorubicin—uterine cancer	0.000245	0.00125	CcSEcCtD
Norfloxacin—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000244	0.00124	CcSEcCtD
Norfloxacin—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000243	0.00124	CcSEcCtD
Norfloxacin—Photosensitivity—Epirubicin—uterine cancer	0.000242	0.00123	CcSEcCtD
Norfloxacin—Dizziness—Progesterone—uterine cancer	0.000241	0.00123	CcSEcCtD
Norfloxacin—Hypertonia—Doxorubicin—uterine cancer	0.000237	0.00121	CcSEcCtD
Norfloxacin—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000237	0.00121	CcSEcCtD
Norfloxacin—Hepatic failure—Epirubicin—uterine cancer	0.000236	0.0012	CcSEcCtD
Norfloxacin—Eye pain—Epirubicin—uterine cancer	0.000235	0.0012	CcSEcCtD
Norfloxacin—Chills—Etoposide—uterine cancer	0.000235	0.0012	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000234	0.00119	CcSEcCtD
Norfloxacin—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000233	0.00119	CcSEcCtD
Norfloxacin—CYP3A4—female reproductive system—uterine cancer	0.000232	0.0146	CbGeAlD
Norfloxacin—Vomiting—Progesterone—uterine cancer	0.000232	0.00118	CcSEcCtD
Norfloxacin—Rash—Progesterone—uterine cancer	0.00023	0.00117	CcSEcCtD
Norfloxacin—Dermatitis—Progesterone—uterine cancer	0.000229	0.00117	CcSEcCtD
Norfloxacin—Headache—Progesterone—uterine cancer	0.000228	0.00116	CcSEcCtD
Norfloxacin—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000226	0.00115	CcSEcCtD
Norfloxacin—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000226	0.00115	CcSEcCtD
Norfloxacin—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000225	0.00115	CcSEcCtD
Norfloxacin—Photosensitivity—Doxorubicin—uterine cancer	0.000224	0.00114	CcSEcCtD
Norfloxacin—Decreased appetite—Dactinomycin—uterine cancer	0.000224	0.00114	CcSEcCtD
Norfloxacin—Dysgeusia—Etoposide—uterine cancer	0.000223	0.00114	CcSEcCtD
Norfloxacin—Dermatitis bullous—Epirubicin—uterine cancer	0.000222	0.00113	CcSEcCtD
Norfloxacin—Fatigue—Dactinomycin—uterine cancer	0.000222	0.00113	CcSEcCtD
Norfloxacin—TOP2A—Levonorgestrel—Progesterone—uterine cancer	0.000221	0.05	CbGdCrCtD
Norfloxacin—Back pain—Etoposide—uterine cancer	0.000221	0.00112	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000219	0.00112	CcSEcCtD
Norfloxacin—Muscle spasms—Etoposide—uterine cancer	0.000219	0.00112	CcSEcCtD
Norfloxacin—Hepatic failure—Doxorubicin—uterine cancer	0.000219	0.00111	CcSEcCtD
Norfloxacin—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000218	0.00111	CcSEcCtD
Norfloxacin—Eye pain—Doxorubicin—uterine cancer	0.000218	0.00111	CcSEcCtD
Norfloxacin—Hypoglycaemia—Epirubicin—uterine cancer	0.000218	0.00111	CcSEcCtD
Norfloxacin—Nausea—Progesterone—uterine cancer	0.000216	0.0011	CcSEcCtD
Norfloxacin—Diplopia—Epirubicin—uterine cancer	0.000212	0.00108	CcSEcCtD
Norfloxacin—Osteoarthritis—Epirubicin—uterine cancer	0.000212	0.00108	CcSEcCtD
Norfloxacin—Feeling abnormal—Dactinomycin—uterine cancer	0.000212	0.00108	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00021	0.00107	CcSEcCtD
Norfloxacin—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00021	0.00107	CcSEcCtD
Norfloxacin—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000208	0.00106	CcSEcCtD
Norfloxacin—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00106	CcSEcCtD
Norfloxacin—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00106	CcSEcCtD
Norfloxacin—SLC22A5—lymph node—uterine cancer	0.000207	0.0131	CbGeAlD
Norfloxacin—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000207	0.00105	CcSEcCtD
Norfloxacin—Dermatitis bullous—Doxorubicin—uterine cancer	0.000206	0.00105	CcSEcCtD
Norfloxacin—Vertigo—Etoposide—uterine cancer	0.000205	0.00104	CcSEcCtD
Norfloxacin—Leukopenia—Etoposide—uterine cancer	0.000204	0.00104	CcSEcCtD
Norfloxacin—Body temperature increased—Dactinomycin—uterine cancer	0.000203	0.00104	CcSEcCtD
Norfloxacin—Abdominal pain—Dactinomycin—uterine cancer	0.000203	0.00104	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000203	0.00103	CcSEcCtD
Norfloxacin—Hypoglycaemia—Doxorubicin—uterine cancer	0.000201	0.00103	CcSEcCtD
Norfloxacin—Ataxia—Epirubicin—uterine cancer	0.0002	0.00102	CcSEcCtD
Norfloxacin—Blood creatinine increased—Epirubicin—uterine cancer	0.000199	0.00101	CcSEcCtD
Norfloxacin—Convulsion—Etoposide—uterine cancer	0.000198	0.00101	CcSEcCtD
Norfloxacin—Diplopia—Doxorubicin—uterine cancer	0.000197	0.001	CcSEcCtD
Norfloxacin—Osteoarthritis—Doxorubicin—uterine cancer	0.000197	0.001	CcSEcCtD
Norfloxacin—Liver function test abnormal—Epirubicin—uterine cancer	0.000196	0.000998	CcSEcCtD
Norfloxacin—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000196	0.000998	CcSEcCtD
Norfloxacin—Chest pain—Etoposide—uterine cancer	0.000194	0.000989	CcSEcCtD
Norfloxacin—Orthostatic hypotension—Epirubicin—uterine cancer	0.000194	0.000988	CcSEcCtD
Norfloxacin—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000191	0.000974	CcSEcCtD
Norfloxacin—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000191	0.000974	CcSEcCtD
Norfloxacin—Hypersensitivity—Dactinomycin—uterine cancer	0.00019	0.000965	CcSEcCtD
Norfloxacin—Confusional state—Etoposide—uterine cancer	0.000188	0.000956	CcSEcCtD
Norfloxacin—Anaphylactic shock—Etoposide—uterine cancer	0.000186	0.000948	CcSEcCtD
Norfloxacin—Ataxia—Doxorubicin—uterine cancer	0.000185	0.000941	CcSEcCtD
Norfloxacin—CYP1A1—lymph node—uterine cancer	0.000185	0.0117	CbGeAlD
Norfloxacin—Asthenia—Dactinomycin—uterine cancer	0.000185	0.00094	CcSEcCtD
Norfloxacin—Blood creatinine increased—Doxorubicin—uterine cancer	0.000184	0.000937	CcSEcCtD
Norfloxacin—Dysphagia—Epirubicin—uterine cancer	0.000184	0.000935	CcSEcCtD
Norfloxacin—Thrombocytopenia—Etoposide—uterine cancer	0.000182	0.000928	CcSEcCtD
Norfloxacin—Eosinophilia—Epirubicin—uterine cancer	0.000182	0.000925	CcSEcCtD
Norfloxacin—Liver function test abnormal—Doxorubicin—uterine cancer	0.000181	0.000924	CcSEcCtD
Norfloxacin—Hyperhidrosis—Etoposide—uterine cancer	0.00018	0.000917	CcSEcCtD
Norfloxacin—Pancreatitis—Epirubicin—uterine cancer	0.00018	0.000916	CcSEcCtD
Norfloxacin—Orthostatic hypotension—Doxorubicin—uterine cancer	0.00018	0.000914	CcSEcCtD
Norfloxacin—Anorexia—Etoposide—uterine cancer	0.000178	0.000904	CcSEcCtD
Norfloxacin—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000177	0.000901	CcSEcCtD
Norfloxacin—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000177	0.000901	CcSEcCtD
Norfloxacin—Diarrhoea—Dactinomycin—uterine cancer	0.000176	0.000896	CcSEcCtD
Norfloxacin—Neutropenia—Epirubicin—uterine cancer	0.000172	0.000874	CcSEcCtD
Norfloxacin—Dysphagia—Doxorubicin—uterine cancer	0.00017	0.000865	CcSEcCtD
Norfloxacin—Eosinophilia—Doxorubicin—uterine cancer	0.000168	0.000856	CcSEcCtD
Norfloxacin—Photosensitivity reaction—Epirubicin—uterine cancer	0.000168	0.000853	CcSEcCtD
Norfloxacin—Paraesthesia—Etoposide—uterine cancer	0.000167	0.000851	CcSEcCtD
Norfloxacin—Pancreatitis—Doxorubicin—uterine cancer	0.000167	0.000848	CcSEcCtD
Norfloxacin—Dyspnoea—Etoposide—uterine cancer	0.000166	0.000845	CcSEcCtD
Norfloxacin—Somnolence—Etoposide—uterine cancer	0.000166	0.000843	CcSEcCtD
Norfloxacin—Drowsiness—Epirubicin—uterine cancer	0.000164	0.000833	CcSEcCtD
Norfloxacin—Vomiting—Dactinomycin—uterine cancer	0.000164	0.000833	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000162	0.000826	CcSEcCtD
Norfloxacin—Rash—Dactinomycin—uterine cancer	0.000162	0.000826	CcSEcCtD
Norfloxacin—Decreased appetite—Etoposide—uterine cancer	0.000162	0.000824	CcSEcCtD
Norfloxacin—Renal failure—Epirubicin—uterine cancer	0.000161	0.000819	CcSEcCtD
Norfloxacin—Fatigue—Etoposide—uterine cancer	0.000161	0.000817	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Epirubicin—uterine cancer	0.00016	0.000817	CcSEcCtD
Norfloxacin—Stomatitis—Epirubicin—uterine cancer	0.00016	0.000812	CcSEcCtD
Norfloxacin—Jaundice—Epirubicin—uterine cancer	0.00016	0.000812	CcSEcCtD
Norfloxacin—Constipation—Etoposide—uterine cancer	0.000159	0.000811	CcSEcCtD
Norfloxacin—Conjunctivitis—Epirubicin—uterine cancer	0.000159	0.00081	CcSEcCtD
Norfloxacin—Neutropenia—Doxorubicin—uterine cancer	0.000159	0.000809	CcSEcCtD
Norfloxacin—Haematuria—Epirubicin—uterine cancer	0.000156	0.000795	CcSEcCtD
Norfloxacin—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000155	0.000789	CcSEcCtD
Norfloxacin—Feeling abnormal—Etoposide—uterine cancer	0.000153	0.000781	CcSEcCtD
Norfloxacin—Nausea—Dactinomycin—uterine cancer	0.000153	0.000778	CcSEcCtD
Norfloxacin—Agranulocytosis—Epirubicin—uterine cancer	0.000153	0.000778	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Etoposide—uterine cancer	0.000152	0.000775	CcSEcCtD
Norfloxacin—Drowsiness—Doxorubicin—uterine cancer	0.000151	0.000771	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00015	0.000764	CcSEcCtD
Norfloxacin—Renal failure—Doxorubicin—uterine cancer	0.000149	0.000758	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000148	0.000756	CcSEcCtD
Norfloxacin—Urticaria—Etoposide—uterine cancer	0.000148	0.000753	CcSEcCtD
Norfloxacin—Stomatitis—Doxorubicin—uterine cancer	0.000148	0.000752	CcSEcCtD
Norfloxacin—Jaundice—Doxorubicin—uterine cancer	0.000148	0.000752	CcSEcCtD
Norfloxacin—Abdominal pain—Etoposide—uterine cancer	0.000147	0.00075	CcSEcCtD
Norfloxacin—Body temperature increased—Etoposide—uterine cancer	0.000147	0.00075	CcSEcCtD
Norfloxacin—Conjunctivitis—Doxorubicin—uterine cancer	0.000147	0.000749	CcSEcCtD
Norfloxacin—Hepatitis—Epirubicin—uterine cancer	0.000147	0.000748	CcSEcCtD
Norfloxacin—Hypoaesthesia—Epirubicin—uterine cancer	0.000146	0.000744	CcSEcCtD
Norfloxacin—Haematuria—Doxorubicin—uterine cancer	0.000144	0.000735	CcSEcCtD
Norfloxacin—Visual impairment—Epirubicin—uterine cancer	0.000142	0.000721	CcSEcCtD
Norfloxacin—Agranulocytosis—Doxorubicin—uterine cancer	0.000141	0.00072	CcSEcCtD
Norfloxacin—Erythema multiforme—Epirubicin—uterine cancer	0.000139	0.000707	CcSEcCtD
Norfloxacin—Hypersensitivity—Etoposide—uterine cancer	0.000137	0.000699	CcSEcCtD
Norfloxacin—Tinnitus—Epirubicin—uterine cancer	0.000137	0.000697	CcSEcCtD
Norfloxacin—Hepatitis—Doxorubicin—uterine cancer	0.000136	0.000692	CcSEcCtD
Norfloxacin—Hypoaesthesia—Doxorubicin—uterine cancer	0.000135	0.000689	CcSEcCtD
Norfloxacin—Asthenia—Etoposide—uterine cancer	0.000134	0.00068	CcSEcCtD
Norfloxacin—Chills—Epirubicin—uterine cancer	0.000132	0.000671	CcSEcCtD
Norfloxacin—Pruritus—Etoposide—uterine cancer	0.000132	0.000671	CcSEcCtD
Norfloxacin—Visual impairment—Doxorubicin—uterine cancer	0.000131	0.000667	CcSEcCtD
Norfloxacin—Erythema multiforme—Doxorubicin—uterine cancer	0.000129	0.000654	CcSEcCtD
Norfloxacin—Erythema—Epirubicin—uterine cancer	0.000128	0.000651	CcSEcCtD
Norfloxacin—Diarrhoea—Etoposide—uterine cancer	0.000127	0.000649	CcSEcCtD
Norfloxacin—Tinnitus—Doxorubicin—uterine cancer	0.000127	0.000645	CcSEcCtD
Norfloxacin—Flatulence—Epirubicin—uterine cancer	0.000126	0.000642	CcSEcCtD
Norfloxacin—Tension—Epirubicin—uterine cancer	0.000126	0.000639	CcSEcCtD
Norfloxacin—Dysgeusia—Epirubicin—uterine cancer	0.000125	0.000638	CcSEcCtD
Norfloxacin—Nervousness—Epirubicin—uterine cancer	0.000124	0.000633	CcSEcCtD
Norfloxacin—Back pain—Epirubicin—uterine cancer	0.000124	0.00063	CcSEcCtD
Norfloxacin—Dizziness—Etoposide—uterine cancer	0.000123	0.000627	CcSEcCtD
Norfloxacin—Muscle spasms—Epirubicin—uterine cancer	0.000123	0.000626	CcSEcCtD
Norfloxacin—Chills—Doxorubicin—uterine cancer	0.000122	0.000621	CcSEcCtD
Norfloxacin—Vision blurred—Epirubicin—uterine cancer	0.000121	0.000614	CcSEcCtD
Norfloxacin—Vomiting—Etoposide—uterine cancer	0.000118	0.000603	CcSEcCtD
Norfloxacin—Erythema—Doxorubicin—uterine cancer	0.000118	0.000603	CcSEcCtD
Norfloxacin—Agitation—Epirubicin—uterine cancer	0.000118	0.000598	CcSEcCtD
Norfloxacin—Rash—Etoposide—uterine cancer	0.000117	0.000598	CcSEcCtD
Norfloxacin—Dermatitis—Etoposide—uterine cancer	0.000117	0.000597	CcSEcCtD
Norfloxacin—Headache—Etoposide—uterine cancer	0.000117	0.000594	CcSEcCtD
Norfloxacin—Flatulence—Doxorubicin—uterine cancer	0.000117	0.000594	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—AKR1C1—uterine cancer	0.000116	0.00528	CbGpPWpGaD
Norfloxacin—Tension—Doxorubicin—uterine cancer	0.000116	0.000591	CcSEcCtD
Norfloxacin—Dysgeusia—Doxorubicin—uterine cancer	0.000116	0.00059	CcSEcCtD
Norfloxacin—Nervousness—Doxorubicin—uterine cancer	0.000115	0.000585	CcSEcCtD
Norfloxacin—Vertigo—Epirubicin—uterine cancer	0.000115	0.000585	CcSEcCtD
Norfloxacin—Leukopenia—Epirubicin—uterine cancer	0.000115	0.000583	CcSEcCtD
Norfloxacin—Back pain—Doxorubicin—uterine cancer	0.000114	0.000583	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—AKR1B1—uterine cancer	0.000114	0.0052	CbGpPWpGaD
Norfloxacin—Muscle spasms—Doxorubicin—uterine cancer	0.000114	0.000579	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—NFE2L2—uterine cancer	0.000113	0.00515	CbGpPWpGaD
Norfloxacin—Palpitations—Epirubicin—uterine cancer	0.000113	0.000575	CcSEcCtD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000112	0.00509	CbGpPWpGaD
Norfloxacin—Vision blurred—Doxorubicin—uterine cancer	0.000112	0.000568	CcSEcCtD
Norfloxacin—Convulsion—Epirubicin—uterine cancer	0.000111	0.000564	CcSEcCtD
Norfloxacin—Nausea—Etoposide—uterine cancer	0.000111	0.000563	CcSEcCtD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000111	0.00503	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000109	0.00497	CbGpPWpGaD
Norfloxacin—Arthralgia—Epirubicin—uterine cancer	0.000109	0.000554	CcSEcCtD
Norfloxacin—Myalgia—Epirubicin—uterine cancer	0.000109	0.000554	CcSEcCtD
Norfloxacin—Chest pain—Epirubicin—uterine cancer	0.000109	0.000554	CcSEcCtD
Norfloxacin—Agitation—Doxorubicin—uterine cancer	0.000109	0.000554	CcSEcCtD
Norfloxacin—Anxiety—Epirubicin—uterine cancer	0.000109	0.000553	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000108	0.00491	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—GPX3—uterine cancer	0.000108	0.00491	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000108	0.00489	CbGpPWpGaD
Norfloxacin—Dry mouth—Epirubicin—uterine cancer	0.000107	0.000542	CcSEcCtD
Norfloxacin—Vertigo—Doxorubicin—uterine cancer	0.000106	0.000541	CcSEcCtD
Norfloxacin—CYP1A2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000106	0.00482	CbGpPWpGaD
Norfloxacin—Leukopenia—Doxorubicin—uterine cancer	0.000106	0.000539	CcSEcCtD
Norfloxacin—Confusional state—Epirubicin—uterine cancer	0.000105	0.000536	CcSEcCtD
Norfloxacin—Palpitations—Doxorubicin—uterine cancer	0.000105	0.000532	CcSEcCtD
Norfloxacin—Oedema—Epirubicin—uterine cancer	0.000104	0.000531	CcSEcCtD
Norfloxacin—Anaphylactic shock—Epirubicin—uterine cancer	0.000104	0.000531	CcSEcCtD
Norfloxacin—Convulsion—Doxorubicin—uterine cancer	0.000103	0.000522	CcSEcCtD
Norfloxacin—Thrombocytopenia—Epirubicin—uterine cancer	0.000102	0.00052	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—GPX3—uterine cancer	0.000102	0.00464	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Epirubicin—uterine cancer	0.000101	0.000514	CcSEcCtD
Norfloxacin—Chest pain—Doxorubicin—uterine cancer	0.000101	0.000513	CcSEcCtD
Norfloxacin—Myalgia—Doxorubicin—uterine cancer	0.000101	0.000513	CcSEcCtD
Norfloxacin—Arthralgia—Doxorubicin—uterine cancer	0.000101	0.000513	CcSEcCtD
Norfloxacin—Anxiety—Doxorubicin—uterine cancer	0.0001	0.000511	CcSEcCtD
Norfloxacin—Anorexia—Epirubicin—uterine cancer	9.95e-05	0.000507	CcSEcCtD
Norfloxacin—Dry mouth—Doxorubicin—uterine cancer	9.86e-05	0.000502	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—NDC80—uterine cancer	9.77e-05	0.00444	CbGpPWpGaD
Norfloxacin—Confusional state—Doxorubicin—uterine cancer	9.74e-05	0.000496	CcSEcCtD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.71e-05	0.00441	CbGpPWpGaD
Norfloxacin—Anaphylactic shock—Doxorubicin—uterine cancer	9.66e-05	0.000492	CcSEcCtD
Norfloxacin—Oedema—Doxorubicin—uterine cancer	9.66e-05	0.000492	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	9.65e-05	0.00439	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.62e-05	0.00437	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—CYP11A1—uterine cancer	9.61e-05	0.00437	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.59e-05	0.00436	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.51e-05	0.000484	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP11A1—uterine cancer	9.47e-05	0.00431	CbGpPWpGaD
Norfloxacin—Thrombocytopenia—Doxorubicin—uterine cancer	9.46e-05	0.000481	CcSEcCtD
Norfloxacin—Insomnia—Epirubicin—uterine cancer	9.44e-05	0.000481	CcSEcCtD
Norfloxacin—Paraesthesia—Epirubicin—uterine cancer	9.38e-05	0.000477	CcSEcCtD
Norfloxacin—Hyperhidrosis—Doxorubicin—uterine cancer	9.34e-05	0.000475	CcSEcCtD
Norfloxacin—Dyspnoea—Epirubicin—uterine cancer	9.31e-05	0.000474	CcSEcCtD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—ABCC9—uterine cancer	9.3e-05	0.00423	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—POLD1—uterine cancer	9.29e-05	0.00422	CbGpPWpGaD
Norfloxacin—Somnolence—Epirubicin—uterine cancer	9.28e-05	0.000472	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	9.26e-05	0.00421	CbGpPWpGaD
Norfloxacin—Anorexia—Doxorubicin—uterine cancer	9.21e-05	0.000469	CcSEcCtD
Norfloxacin—Dyspepsia—Epirubicin—uterine cancer	9.19e-05	0.000468	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	9.17e-05	0.00417	CbGpPWpGaD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.09e-05	0.00413	CbGpPWpGaD
Norfloxacin—Decreased appetite—Epirubicin—uterine cancer	9.08e-05	0.000462	CcSEcCtD
Norfloxacin—Fatigue—Epirubicin—uterine cancer	9e-05	0.000458	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—AKR1C3—uterine cancer	8.95e-05	0.00407	CbGpPWpGaD
Norfloxacin—Constipation—Epirubicin—uterine cancer	8.93e-05	0.000455	CcSEcCtD
Norfloxacin—CYP1A2—Tryptophan metabolism—CYP19A1—uterine cancer	8.84e-05	0.00402	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—CYP11A1—uterine cancer	8.81e-05	0.004	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.8e-05	0.000448	CcSEcCtD
Norfloxacin—Insomnia—Doxorubicin—uterine cancer	8.74e-05	0.000445	CcSEcCtD
Norfloxacin—Paraesthesia—Doxorubicin—uterine cancer	8.67e-05	0.000442	CcSEcCtD
Norfloxacin—Dyspnoea—Doxorubicin—uterine cancer	8.61e-05	0.000438	CcSEcCtD
Norfloxacin—Feeling abnormal—Epirubicin—uterine cancer	8.6e-05	0.000438	CcSEcCtD
Norfloxacin—Somnolence—Doxorubicin—uterine cancer	8.59e-05	0.000437	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Epirubicin—uterine cancer	8.54e-05	0.000435	CcSEcCtD
Norfloxacin—Dyspepsia—Doxorubicin—uterine cancer	8.5e-05	0.000433	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—AKR1C1—uterine cancer	8.4e-05	0.00382	CbGpPWpGaD
Norfloxacin—Decreased appetite—Doxorubicin—uterine cancer	8.4e-05	0.000427	CcSEcCtD
Norfloxacin—Fatigue—Doxorubicin—uterine cancer	8.33e-05	0.000424	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—POLD1—uterine cancer	8.31e-05	0.00378	CbGpPWpGaD
Norfloxacin—Urticaria—Epirubicin—uterine cancer	8.29e-05	0.000422	CcSEcCtD
Norfloxacin—Constipation—Doxorubicin—uterine cancer	8.26e-05	0.000421	CcSEcCtD
Norfloxacin—Body temperature increased—Epirubicin—uterine cancer	8.25e-05	0.00042	CcSEcCtD
Norfloxacin—Abdominal pain—Epirubicin—uterine cancer	8.25e-05	0.00042	CcSEcCtD
Norfloxacin—Feeling abnormal—Doxorubicin—uterine cancer	7.96e-05	0.000405	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—AKR1C1—uterine cancer	7.94e-05	0.00361	CbGpPWpGaD
Norfloxacin—Gastrointestinal pain—Doxorubicin—uterine cancer	7.9e-05	0.000402	CcSEcCtD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.88e-05	0.00358	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—RRM2—uterine cancer	7.75e-05	0.00352	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Epirubicin—uterine cancer	7.69e-05	0.000392	CcSEcCtD
Norfloxacin—Urticaria—Doxorubicin—uterine cancer	7.67e-05	0.000391	CcSEcCtD
Norfloxacin—Abdominal pain—Doxorubicin—uterine cancer	7.64e-05	0.000389	CcSEcCtD
Norfloxacin—Body temperature increased—Doxorubicin—uterine cancer	7.64e-05	0.000389	CcSEcCtD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	7.5e-05	0.00341	CbGpPWpGaD
Norfloxacin—Asthenia—Epirubicin—uterine cancer	7.49e-05	0.000381	CcSEcCtD
Norfloxacin—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	7.42e-05	0.00337	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	7.4e-05	0.00336	CbGpPWpGaD
Norfloxacin—Pruritus—Epirubicin—uterine cancer	7.39e-05	0.000376	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—GPX3—uterine cancer	7.38e-05	0.00335	CbGpPWpGaD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	7.29e-05	0.00331	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	7.19e-05	0.00327	CbGpPWpGaD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	7.15e-05	0.00325	CbGpPWpGaD
Norfloxacin—Diarrhoea—Epirubicin—uterine cancer	7.14e-05	0.000364	CcSEcCtD
Norfloxacin—Hypersensitivity—Doxorubicin—uterine cancer	7.12e-05	0.000362	CcSEcCtD
Norfloxacin—CYP3A7—Biological oxidations—CYP19A1—uterine cancer	7.07e-05	0.00321	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	7.05e-05	0.00321	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.02e-05	0.00319	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP19A1—uterine cancer	6.97e-05	0.00317	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—GPX3—uterine cancer	6.97e-05	0.00317	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP11A1—uterine cancer	6.94e-05	0.00316	CbGpPWpGaD
Norfloxacin—Asthenia—Doxorubicin—uterine cancer	6.93e-05	0.000353	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—RRM2—uterine cancer	6.93e-05	0.00315	CbGpPWpGaD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—TP53—uterine cancer	6.92e-05	0.00315	CbGpPWpGaD
Norfloxacin—Dizziness—Epirubicin—uterine cancer	6.9e-05	0.000351	CcSEcCtD
Norfloxacin—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	6.9e-05	0.00313	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	6.85e-05	0.00311	CbGpPWpGaD
Norfloxacin—Pruritus—Doxorubicin—uterine cancer	6.83e-05	0.000348	CcSEcCtD
Norfloxacin—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	6.82e-05	0.0031	CbGpPWpGaD
Norfloxacin—Vomiting—Epirubicin—uterine cancer	6.64e-05	0.000338	CcSEcCtD
Norfloxacin—Diarrhoea—Doxorubicin—uterine cancer	6.61e-05	0.000336	CcSEcCtD
Norfloxacin—Rash—Epirubicin—uterine cancer	6.58e-05	0.000335	CcSEcCtD
Norfloxacin—Dermatitis—Epirubicin—uterine cancer	6.58e-05	0.000335	CcSEcCtD
Norfloxacin—CYP1A1—Biological oxidations—CYP11A1—uterine cancer	6.56e-05	0.00298	CbGpPWpGaD
Norfloxacin—Headache—Epirubicin—uterine cancer	6.54e-05	0.000333	CcSEcCtD
Norfloxacin—CYP2A6—Biological oxidations—CYP19A1—uterine cancer	6.48e-05	0.00294	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP11A1—uterine cancer	6.47e-05	0.00294	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	6.47e-05	0.00294	CbGpPWpGaD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	6.45e-05	0.00293	CbGpPWpGaD
Norfloxacin—Dizziness—Doxorubicin—uterine cancer	6.39e-05	0.000325	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	6.29e-05	0.00286	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	6.29e-05	0.00286	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—YWHAE—uterine cancer	6.22e-05	0.00283	CbGpPWpGaD
Norfloxacin—Nausea—Epirubicin—uterine cancer	6.2e-05	0.000316	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—MLH1—uterine cancer	6.15e-05	0.00279	CbGpPWpGaD
Norfloxacin—Vomiting—Doxorubicin—uterine cancer	6.14e-05	0.000313	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—AKR1C3—uterine cancer	6.11e-05	0.00278	CbGpPWpGaD
Norfloxacin—Rash—Doxorubicin—uterine cancer	6.09e-05	0.00031	CcSEcCtD
Norfloxacin—Dermatitis—Doxorubicin—uterine cancer	6.09e-05	0.00031	CcSEcCtD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.08e-05	0.00276	CbGpPWpGaD
Norfloxacin—Headache—Doxorubicin—uterine cancer	6.05e-05	0.000308	CcSEcCtD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	5.9e-05	0.00268	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.82e-05	0.00265	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.79e-05	0.00263	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	5.76e-05	0.00262	CbGpPWpGaD
Norfloxacin—Nausea—Doxorubicin—uterine cancer	5.74e-05	0.000292	CcSEcCtD
Norfloxacin—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.72e-05	0.0026	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—YWHAE—uterine cancer	5.56e-05	0.00253	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	5.53e-05	0.00251	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	5.53e-05	0.00251	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.52e-05	0.00251	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.44e-05	0.00247	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.32e-05	0.00242	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	5.28e-05	0.0024	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	5.23e-05	0.00238	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	5.17e-05	0.00235	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	5.11e-05	0.00232	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	5.06e-05	0.0023	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	5.04e-05	0.00229	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	4.89e-05	0.00222	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—CYP19A1—uterine cancer	4.83e-05	0.00219	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP19A1—uterine cancer	4.76e-05	0.00216	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	4.67e-05	0.00212	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	4.62e-05	0.0021	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	4.5e-05	0.00205	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.47e-05	0.00203	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	4.45e-05	0.00202	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	4.44e-05	0.00202	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—PTEN—uterine cancer	4.32e-05	0.00196	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	4.29e-05	0.00195	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.21e-05	0.00191	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.21e-05	0.00191	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	4.18e-05	0.0019	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—CDKN2B—uterine cancer	4.18e-05	0.0019	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	4.13e-05	0.00187	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—EP300—uterine cancer	4.12e-05	0.00187	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	4.07e-05	0.00185	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—BIRC5—uterine cancer	4.03e-05	0.00183	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	4.01e-05	0.00182	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	4.01e-05	0.00182	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.91e-05	0.00178	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	3.9e-05	0.00177	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—SRD5A2—uterine cancer	3.8e-05	0.00173	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—NDUFB11—uterine cancer	3.8e-05	0.00173	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	3.78e-05	0.00172	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.71e-05	0.00169	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—BIRC5—uterine cancer	3.61e-05	0.00164	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	3.52e-05	0.0016	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	3.52e-05	0.0016	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—NDUFB11—uterine cancer	3.48e-05	0.00158	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—SRD5A2—uterine cancer	3.48e-05	0.00158	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	3.46e-05	0.00157	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.43e-05	0.00156	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	3.34e-05	0.00152	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	3.3e-05	0.0015	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.23e-05	0.00147	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.18e-05	0.00145	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.18e-05	0.00144	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.09e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	3.08e-05	0.0014	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.07e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	3.04e-05	0.00138	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.01e-05	0.00137	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—TP53—uterine cancer	2.95e-05	0.00134	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	2.84e-05	0.00129	CbGpPWpGaD
Norfloxacin—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	2.75e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—AKR1B1—uterine cancer	2.75e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—STAR—uterine cancer	2.75e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—NDUFB11—uterine cancer	2.75e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—SRD5A2—uterine cancer	2.75e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	2.69e-05	0.00122	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.68e-05	0.00122	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.68e-05	0.00122	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	2.67e-05	0.00121	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.59e-05	0.00118	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—SRD5A2—uterine cancer	2.59e-05	0.00118	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—NDUFB11—uterine cancer	2.59e-05	0.00118	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.52e-05	0.00114	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—STAR—uterine cancer	2.52e-05	0.00114	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—AKR1B1—uterine cancer	2.52e-05	0.00114	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	2.41e-05	0.0011	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—CDKN2A—uterine cancer	2.39e-05	0.00109	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.38e-05	0.00108	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.38e-05	0.00108	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	2.37e-05	0.00108	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.34e-05	0.00106	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—POLD1—uterine cancer	2.15e-05	0.000979	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—CDKN1B—uterine cancer	2.12e-05	0.000962	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—EP300—uterine cancer	2.08e-05	0.000944	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—AKR1C1—uterine cancer	2.02e-05	0.000916	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—AKR1B1—uterine cancer	1.98e-05	0.000902	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—STAR—uterine cancer	1.98e-05	0.000902	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—POLD1—uterine cancer	1.97e-05	0.000898	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.97e-05	0.000896	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—AKR1B1—uterine cancer	1.88e-05	0.000852	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—STAR—uterine cancer	1.88e-05	0.000852	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—EP300—uterine cancer	1.86e-05	0.000844	CbGpPWpGaD
Norfloxacin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	1.86e-05	0.000843	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.85e-05	0.000842	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—AKR1C1—uterine cancer	1.85e-05	0.00084	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—RRM2—uterine cancer	1.8e-05	0.000816	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—DCN—uterine cancer	1.74e-05	0.000793	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—SRD5A2—uterine cancer	1.65e-05	0.000752	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—NDUFB11—uterine cancer	1.65e-05	0.000752	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—RRM2—uterine cancer	1.65e-05	0.000748	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP11A1—uterine cancer	1.64e-05	0.000747	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.61e-05	0.00073	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—DCN—uterine cancer	1.6e-05	0.000726	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—POLD1—uterine cancer	1.56e-05	0.000708	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—AKR1C3—uterine cancer	1.55e-05	0.000705	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.52e-05	0.000689	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP11A1—uterine cancer	1.51e-05	0.000684	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—POLD1—uterine cancer	1.47e-05	0.000669	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.46e-05	0.000662	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—AKR1C3—uterine cancer	1.42e-05	0.000646	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—AKR1C1—uterine cancer	1.38e-05	0.000625	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—TP53—uterine cancer	1.33e-05	0.000604	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—RRM2—uterine cancer	1.3e-05	0.00059	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.28e-05	0.00058	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.28e-05	0.00058	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—DCN—uterine cancer	1.26e-05	0.000573	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—RRM2—uterine cancer	1.23e-05	0.000558	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—STK11—uterine cancer	1.21e-05	0.000549	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP19A1—uterine cancer	1.21e-05	0.000549	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—STAR—uterine cancer	1.2e-05	0.000543	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.2e-05	0.000543	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—DCN—uterine cancer	1.19e-05	0.000541	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.00054	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.18e-05	0.000537	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.12e-05	0.00051	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—AKR1C3—uterine cancer	1.12e-05	0.00051	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—STK11—uterine cancer	1.11e-05	0.000504	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP19A1—uterine cancer	1.11e-05	0.000504	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.06e-05	0.000482	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—POLD1—uterine cancer	9.38e-06	0.000426	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.23e-06	0.000419	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—STAR—uterine cancer	9.23e-06	0.000419	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—MTHFR—uterine cancer	9.08e-06	0.000413	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—AKR1C1—uterine cancer	8.78e-06	0.000399	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—STK11—uterine cancer	8.74e-06	0.000397	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP19A1—uterine cancer	8.74e-06	0.000397	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—MTHFR—uterine cancer	8.33e-06	0.000378	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—STK11—uterine cancer	8.25e-06	0.000375	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP19A1—uterine cancer	8.25e-06	0.000375	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—RRM2—uterine cancer	7.82e-06	0.000355	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.75e-06	0.000352	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—DCN—uterine cancer	7.59e-06	0.000345	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.39e-06	0.000336	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—POLD1—uterine cancer	7.24e-06	0.000329	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP11A1—uterine cancer	7.15e-06	0.000325	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.77e-06	0.000308	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—AKR1C3—uterine cancer	6.76e-06	0.000307	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—MTHFR—uterine cancer	6.57e-06	0.000298	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—MTHFR—uterine cancer	6.2e-06	0.000282	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—RRM2—uterine cancer	6.04e-06	0.000274	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—DCN—uterine cancer	5.86e-06	0.000266	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.52e-06	0.000251	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.47e-06	0.000248	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—STK11—uterine cancer	5.26e-06	0.000239	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP19A1—uterine cancer	5.26e-06	0.000239	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.21e-06	0.000237	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—PTEN—uterine cancer	5.05e-06	0.00023	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.94e-06	0.000225	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—EP300—uterine cancer	4.82e-06	0.000219	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.71e-06	0.000214	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—PTEN—uterine cancer	4.63e-06	0.00021	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—EP300—uterine cancer	4.42e-06	0.000201	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—STK11—uterine cancer	4.06e-06	0.000185	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.06e-06	0.000185	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—MTHFR—uterine cancer	3.96e-06	0.00018	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—PTEN—uterine cancer	3.65e-06	0.000166	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.56e-06	0.000162	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.49e-06	0.000158	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—EP300—uterine cancer	3.48e-06	0.000158	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—PTEN—uterine cancer	3.45e-06	0.000157	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—EP300—uterine cancer	3.29e-06	0.00015	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—PIK3CA—uterine cancer	3.27e-06	0.000148	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—MTHFR—uterine cancer	3.05e-06	0.000139	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—AKT1—uterine cancer	2.91e-06	0.000132	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—AKT1—uterine cancer	2.67e-06	0.000121	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.58e-06	0.000117	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.43e-06	0.000111	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—PTEN—uterine cancer	2.2e-06	0.0001	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—AKT1—uterine cancer	2.11e-06	9.57e-05	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—EP300—uterine cancer	2.1e-06	9.54e-05	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—AKT1—uterine cancer	1.99e-06	9.04e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—PTEN—uterine cancer	1.7e-06	7.72e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—EP300—uterine cancer	1.62e-06	7.36e-05	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.55e-06	7.05e-05	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—AKT1—uterine cancer	1.27e-06	5.76e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.2e-06	5.44e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—AKT1—uterine cancer	9.79e-07	4.45e-05	CbGpPWpGaD
